Oakland-based Omicia Inc, a provider of clinical genome interpretation and reporting software, announced it has raised a little more than $23 million in Series B funding. Several new investors participated in the round, including UPMC Enterprises, Roche Venture Fund, LDV Partners, Ping An Ventures, and a large genomics investor, as well as existing investors ARTIS Ventures, Acadia Woods Partners and Buchanan Investments. Omicia says it has now raised about $31.5 million, including a $6.8 million Series A round and $1.5 million in seed funding.